SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (1995)10/2/1997 12:43:00 PM
From: Peter Silsbee   of 6136
 
I agree completely about needing to know the definition of "responding," and I also agree (and stated) that extrapolation from this curve is iffy (maybe I should have said "iffy at best.") But my point, such as it is, was that the slope of the curve appears to approach zero faster than the total number of "responding patients" approaches zero. In fact, even a linear fit to the last twelve weeks gives a failure rate closer to 5% than 10% per year , and it seems to me, from eyeballing the graph, that a linear fit would be pessimistic.

Of course, this all needs to be considered in the context of newer data, esp. that concerned with "real-world" usage of the drug.

BTW, I too welcome your presence on the thread.

PLS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News